Keymed: FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies

CHENGDU, China, April 20, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for

Related Keywords

China ,Chengdu ,Sichuan ,Prnewswire Keymed Biosciences ,Drug Administration ,Track Designation ,Orphan Drug Designation ,Keymed ,Granted ,Cmg901 ,Mast ,Track ,Resignation ,Unresectable ,Metastatic ,Pastric ,Gastroesophageal ,Junction ,Dancer ,Which ,Wave ,Relapsed ,Refractory ,Approved ,Therapies ,